Biogen Inc., a biopharma giant, is making significant strides in the biotech market. The company is now recognized as a top-value stock for long-term investments due to its consistent efforts to realign resources for Alzheimer's franchise. One of the company's promising drugs,
Felzartamab, for treating antibody-mediated kidney rejection received
Breakthrough Therapy Designation from the U.S. FDA. Additionally, its Alzheimer's drug,
Leqembi, is gaining traction, exceeding expectations, and contributing to the hike in the company's outlook. Biogen also announced a collaboration with Beckman Coulter and Fujirebio to develop blood-based biomarkers and tests for Alzheimer's disease. Remarkably, the company announced positive results from its study of Nusinersen, finding significant benefit in the treatment of SMA. However, investors should note that Biogen's stock has decreased by 32% over the last three years. The company has received various approvals for
Leqembi for the Treatment of Alzheimer's Disease in different countries including Great Britain, Israel, and its launch in China. Nevertheless, the company faced some setbacks with termination of collaboration with Sage Therapeutics for Neurological Disorder Candidate and the rejection of its Alzheimer's drug in Europe.
Biogen BIIB News Analytics from Fri, 15 Dec 2023 08:00:00 GMT to Thu, 10 Oct 2024 21:01:14 GMT -
Rating 2
- Innovation 4
- Information 6
- Rumor -3
